Supernus Pharmaceuticals Investor Relations Material
Latest events
Q2 2024
Supernus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Supernus Pharmaceuticals Inc
Access all reports
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its lead product candidate is Duopa (levodopa-carbidopa intestinal gel), a combination of levodopa and carbidopa for the treatment of Parkinson's disease in adults experiencing end-of-dose wearing off and end-of-dose dyskinesia; and ondansetron hydrochloride injectable suspension, which is being developed as a potential next generation form of treatment for chemotherapy-induced nausea and vomiting.
Key slides for Supernus Pharmaceuticals Inc
Status Update
Supernus Pharmaceuticals Inc
Status Update
Supernus Pharmaceuticals Inc
Latest articles
Cristiano Amon: Qualcomm's 5G Specialist CEO
Cristiano Amon, Qualcomm CEO, has spent two decades at the company while taking on several roles, developing both technical and business expertise.
16 Sep 2024
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Ticker symbol
SUPN
Country
🇺🇸 United States